Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles

被引：6
|
作者：
Lin, Hung-Yao [1 ]
Tseng, Tai-Chung [1 ,2 ,3 ]
机构：
[1] Natl Taiwan Univ Hosp, Div Gastroenterol & Hepatol, Dept Internal Med, Taipei, Taiwan
[2] Natl Taiwan Univ Hosp, Hepatitis Res Ctr, Taipei, Taiwan
[3] Natl Taiwan Univ Hosp, Dept Med Res, 1 Chang Te St, Taipei 10002, Taiwan
来源：
CLINICAL AND MOLECULAR HEPATOLOGY | 2022年 / 28卷 / 02期
关键词：
Tenofovir disoproxil fumarate; Tenofovir alafenamide; Hyperlipidemias; Tenofovir;
D O I：
10.3350/cmh.2022.0028
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：181 / 182
页数：2
相关论文
共 50 条
  • [41] Observational pilot study of switching from entecavir to tenofovir alafenamide in patients with chronic hepatitis B
    Matsubara, Takuya
    Hagiwara, Satoru
    Nishida, Naoshi
    Omaru, Naoya
    Yoshida, Akihiro
    Yamamoto, Tomoki
    Komeda, Yoriaki
    Takenaka, Mamoru
    Kudo, Masatoshi
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [42] No Resistance to Tenofovir Alafenamide Detected Through 48 Weeks of Treatment in Patients with Chronic Hepatitis B
    Chan, Henry Lik-Yuen
    Fung, Scott
    Cathcart, Andrea L.
    Liu, Yang
    Ku, Karin S.
    Flaherty, John F.
    Miller, Michael D.
    Gaggar, Anuj
    Kitrinos, Kathryn M.
    Lim, Young-Suk
    Buti, Maria
    HEPATOLOGY, 2016, 64 : 909A - 909A
  • [43] One-year efficacy of tenofovir alafenamide in patients with chronic hepatitis B An observational study
    Chen, Yi-Cheng
    Hsu, Chao-Wei
    Chien, Rong-Nan
    Tai, Dar-In
    MEDICINE, 2022, 101 (25) : E29269
  • [44] EFFECTIVENESS AND SAFETY OF TENOFOVIR ALAFENAMIDE IN CHRONIC HEPATITIS B PATIENTS WITH SUBOPTIMAL RESPONSE TO ANTIVIRAL THERAPY
    Xie, Wen
    Cao, Lihua
    Dang, Shuangsuo
    Zhu, Liying
    Yang, Dongliang
    Zhu, Yueyong
    Dou, Xiaoguang
    Gao, Zhiliang
    Chen, Binbin
    Zhang, Xinxin
    Wang, Yuming
    Liu, Yan
    Zhang, Ting
    Ye, Tingdan
    Mi, Ke
    Pan, Calvin
    HEPATOLOGY, 2024, 80 : S199 - S200
  • [45] Efficacy and safety of tenofovir alafenamide in patients with chronic hepatitis B exhibiting suboptimal response to entecavir
    Yuan, Gui-Cai
    Chen, Ai-Zhen
    Wang, Wei-Xin
    Yi, Xu-Lan
    Tu, Long
    Peng, Fang
    Qiu, Zhi-Hong
    WORLD JOURNAL OF CLINICAL CASES, 2023, 11 (34) : 8139 - 8146
  • [46] No Resistance to Tenofovir Alafenamide Detected through 144 Weeks of Treatment in Patients with Chronic Hepatitis B
    Chan, Henry Lik Yuen
    Marcellin, Patrick
    Pan, Calvin Q.
    Cathcart, Andrea
    Bhardwaj, Neeru
    Liu, Yang
    Parhy, Bandita
    Zhou, Eric
    Hsieh, David
    Chang, Silvia
    Martin, Ross
    Feierbach, Becket
    Mo, Hongmei
    Gaggar, Anuj
    Flaherty, John F.
    Shalimar
    Izumi, Namiki
    Lim, Young-Suk
    HEPATOLOGY, 2018, 68 : 231A - 231A
  • [47] Impact of switching to tenofovir alafenamide fumarate in patients with entecavir-treated chronic hepatitis B
    Kumada, Takashi
    Toyoda, Hidenori
    Yasuda, Satoshi
    Ito, Takanori
    Tanaka, Junko
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 33 : E898 - E904
  • [48] CLINICAL CHARACTERISTICS OF CHRONIC HEPATITIS B PATIENTS RECEIVING TENOFOVIR ALAFENAMIDE TREATMENT IN HONG KONG
    Bang, Lilian Yan
    Wong, Vincent
    Yip, Terry Cheuk-Fung
    Tse, Yee-Kit
    Hui, Vicki Wing Ki
    Lui, Grace Chung-Yan
    Chan, Henry Lik Yuen
    Wong, Grace L. H.
    HEPATOLOGY, 2020, 72 : 478A - 478A
  • [49] Impact of switching to tenofovir alafenamide fumarate in patients with entecavir-treated chronic hepatitis B
    Kumada, Takashi
    Toyoda, Hidenori
    Yasuda, Satoshi
    Ito, Takanori
    Tanaka, Junko
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 33 (1S) : E898 - E904
  • [50] NO RESISTANCE TO TENOFOVIR ALAFENAMIDE DETECTED THROUGH 96 WEEKS OF TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS B
    Chan, Henry Lik-Yeun
    Marcellin, Patrick
    Cathcart, Andrew L.
    Bhardwaj, Neeru
    Flaherty, John F.
    Gaggar, Anuj
    Izumi, Namiki
    Lim, Young-Suk
    GUT, 2018, 67 : A96 - A97
12345